Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia

References

• Meyers F J, Welborn J, Lewis J P, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7: 173–178
   PubMed Web of Science ®Google Scholar
• Martinez J A, Martin G, Sanz G F, Sempere A, Jarque I, de la Rubia J, et al. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 1991; 9: 39–43
   PubMed Web of Science ®Google Scholar
• Vogler W R, Harrington D P, Winton E F, Lazarus H M, Bennett J M, Cassileth P A, et al. Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia 1992; 6: 1072–1075
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146–1151
   PubMed Web of Science ®Google Scholar
• Rowinsky E K, Adjei A, Donehower R C, Gore S D, Jones R J, Burke P J, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193–2203
   PubMed Web of Science ®Google Scholar
• Furman W L, Baker S D, Pratt C B, Rivera G K, Evans W E, Stewart C F. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996; 14: 1504–1511
   PubMed Web of Science ®Google Scholar
• Kaufmann S H, Peereboom D, Buckwalter C A, Svingen P A, Grochow L B, Donehower R C, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734–741
   PubMed Web of Science ®Google Scholar
• Cheng M F, Chatterjee S, Berger N A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994; 6: 269–279
   PubMed Web of Science ®Google Scholar
• Ma J, Maliepaard M, Nooter K, Boersma A W, Verweij J, Stoter G, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998; 41: 307–316
   PubMed Web of Science ®Google Scholar
• Cooper B W, Veal G J, Radivoyevitch T, Tilby M J, Meyerson H J, Lazarus H M, et al. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clin Cancer Res 2004; 10: 6830–6839
   PubMed Web of Science ®Google Scholar
• Kaufmann S H, Karp J E, Letendre L, Kottke T J, Safgren S, Greer J, et al. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res 2005; 11: 6641–6649
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721
   PubMed Web of Science ®Google Scholar
• Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637–2644
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958–965
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple J P, Welch W R, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Vermeulen P B, Gasparini G, Fox S B, Toi M, Martin L, McCulloch P, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474–2484
   PubMed Web of Science ®Google Scholar
• Brown L D. Interval estimation for a binomial proportion. Stat Sci 2001; 16: 101–133
   Web of Science ®Google Scholar
• Breems D A, Van Putten W L, Huijgens P C, Ossenkoppele G J, Verhoef G E, Verdonck L F, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978
   PubMed Web of Science ®Google Scholar
• Leopold L H, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002; 43: 1715–1727
   PubMed Web of Science ®Google Scholar
• Litzow M R. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2007; 14: 130–137
   PubMed Web of Science ®Google Scholar
• Visani G, Tosi P, Zinzani P L, Manfroi S, Ottaviani E, Testoni N, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemias. Leukemia 1994; 8: 1842–1846
   PubMed Web of Science ®Google Scholar
• Steinmetz H T, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999; 78: 418–425
   PubMed Web of Science ®Google Scholar
• Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol 2006; 85: 717–722
   PubMed Web of Science ®Google Scholar
• Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, et al. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004; 83: 696–703
   PubMed Web of Science ®Google Scholar
• Marcucci G, Byrd J C, Dai G, Klisovic M I, Kourlas P J, Young D C, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425–432
   PubMed Web of Science ®Google Scholar
• Karp J E, Gojo I, Pili R, Gocke C D, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-{beta}-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577–3585
   PubMed Web of Science ®Google Scholar
• Stone R M, DeAngelo D J, Klimek V, Galinsky I, Estey E, Nimer S D, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54–60
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Lancet J E, Reiffers J, Lowenberg B, Thomas X, Huguet F, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007; 109: 5151–5156
   PubMed Web of Science ®Google Scholar
• Larson R A, Sievers E L, Stadtmauer E A, Lowenberg B, Estey E H, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 1442–1452
   PubMed Web of Science ®Google Scholar
• Steins M B, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839
   PubMed Web of Science ®Google Scholar
• Thomas D A, Estey E, Giles F J, Faderl S, Cortes J, Keating M, et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2003; 123: 436–441
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2003; 97: 1234–1241
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508–515
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35
   PubMedGoogle Scholar
• Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187–192
   PubMed Web of Science ®Google Scholar
• Corso A, Lorenzi A, Terulla V, Airo F, Varettoni M, Mangiacavalli S, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83: 588–591
   PubMed Web of Science ®Google Scholar
• Kaushal V, Kaushal G P, Melkaveri S N, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004; 2: 327–334
   PubMed Web of Science ®Google Scholar
• De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3: 1985–1992
   PubMed Web of Science ®Google Scholar
• Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23: 5334–5346
   PubMed Web of Science ®Google Scholar